Literature DB >> 6734031

Cefonicid kinetics in subjects with normal and impaired renal function.

A D Blair, B M Maxwell, S C Forland, L Jacob, R E Cutler.   

Abstract

Cefonicid is a cephalosporin with a longer t1/2 than currently available cephalosporins. Cefonicid kinetics after an intravenous dose of 7.5 mg/kg were followed in four groups of subjects: group 1, four subjects with normal creatinine clearance (Clcr greater than 80 ml/min); group II, seven subjects with mild renal insufficiency (Clcr 50 to 80 ml/min); group III, five subjects with moderate to severe renal impairment (Clcr 8 to 49 ml/min); and group IV, five subjects with end-stage renal disease who were receiving maintenance hemodialysis (Clcr less than 8 ml/ml). Cefonicid volume of distribution ranged from 6.9% to 17.6% body weight but was not related to Clcr. Elimination t1/2 was 4.6 +/- 0.7 hr in group 1,6.0 +/- 2.7 hr in group II, 25.6 +/- 14.0 hr in group III, and 65.3 +/- 43.6 hr in group IV. There was a strong correlation between plasma cefonicid clearance and Clcr. Nonrenal clearance did not change with decreasing Clcr. Hemodialysis clearance calculated from plasma concentrations and recovery in dialysate was 2.5 +/- 0.9 ml/min. These kinetic parameters were used to formulate dosage regimens for patients with renal impairment.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6734031     DOI: 10.1038/clpt.1984.115

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  7 in total

1.  Pharmacokinetics of cefonicid in children.

Authors:  M Furlanut; R D'Elia; E Riva; F Pasinelli
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

2.  Effect of age and renal function on cefonicid pharmacokinetics.

Authors:  J M Trang; T P Monson; B H Ackerman; F L Underwood; J T Manning; G L Kearns
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

Review 4.  Cefonicid. A review of its antibacterial activity, pharmacological properties and therapeutic use.

Authors:  E Saltiel; R N Brogden
Journal:  Drugs       Date:  1986-09       Impact factor: 9.546

5.  Pharmacokinetics of cefonicid in patients with skin and skin structure infections.

Authors:  K L Heim-Duthoy; G L Peltier; D R Guay; G R Matzke
Journal:  Antimicrob Agents Chemother       Date:  1988-04       Impact factor: 5.191

6.  Randomized, double-blind trial of cefonicid and nafcillin in the treatment of skin and skin structure infections.

Authors:  J S Daly; M G Worthington; R J Andrews; R B Brown; R Schwartz; D J Sexton
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

7.  Cross-over study of the pharmacokinetics of cefonicid administered intravenously or intramuscularly to healthy adult humans.

Authors:  J B Fourtillan; A Leroy; M A Lefebvre; G Humbert; J P Fillastre; G Reumont; N Ramis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1985 Jul-Sep       Impact factor: 2.441

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.